Diabetes: Intarcia pulls down $210M for drug-device combo| Wall Street Beat

November 16, 2012 By MassDevice staff

Intarcia Therapeutics said it’s reeled in financing worth a total of $210 million to further its drug-device combination treatment for Type II diabetes.

The Hayward, Calif.-based company, which is moving its headquarters to Boston, said the cash will also help facilitate the move.

Intarcia is developing ITCA 650, a matchstick-sized, miniature osmotic pump inserted subcutaneously to deliver the drug exenatide for 1 year. The company is planning a Phase III trial of the technology early next year, according to a press release.

The funding round, which Intarcia claims is biotech’s largest in at least 25 years, involved a $160 million private placement and a $50 million debt round. Backers included existing investors New Enterprise Associates, New Leaf Venture Partners and Venrock and new investors The Baupost Group, Farallon Capital Management and "3 additional top-tier institutional investors based in Boston and New York," according to the release.

"With this landmark financing in place, we have fully preserved the vision for our company and our aim to bring potentially revolutionary clinical, economic and humanistic benefits to millions of diabetes patients around the world," chairman, president & CEO Kurt Graves said in prepared remarks.

Intarcia said it plans to keep its R&D and manufacturing operations in Hayward.

OptiMedica raises $35 million
OptiMedica said it closed a $35 million financing round from all of its existing backers, including Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital. Proceeds will go toward commercializing its Catalys precision laser for cataract surgery.
Read more

Cynosure discounts offering
Cynosure (NSDQ:CYNO) priced its 3.2 million-share public offering $20.50 per share, a 3.3% discount from its closing price yesterday of $21.20 per share. CYNO shares were trading at $21.78 today as of about 12:15 p.m., up 2.7% on the day.
Read more

Allergan drops $350M on SkinMedica
Allergan (NYSE:AGN) agreed to acquire SkinMedica’s topical aesthetics skin care business for $350 million up front and another $25 million pegged to sales milestones. The buyout, expected to close later this year, does not include SkinMedica’s Colorescience aesthetic make-up line, which SkinMedica plans to spin out as a separate company.
Read more

InspireMD delays $40M offering
InspireMD (OTC:NSPR) said it’s postponing a planned, $40 million public stock offering "based on recent adverse market conditions."
Read more

Analysts’ ups and downs

AtriCure (NSDQ:ATRC): Piper Jaffray upgrades from "neutral" to "overweight" rating, increases price target from $6 to $10.
Baxter (NYSE:BAX): Barclays maintains “equal weight” rating, raises price target from $63 to $68; Leerink Swann reiterates “outperform” rating, raises price target to $74 from $70.
Varian Medical (NYSE:VAR): Benchmark Company initiates coverage with “buy” rating, $88 price target.

Using gold nanoparticles to detect COVID-19
Scientists from the University of Maryland School of Medicine have developed an experimental diagnostic test for COVID-19 that they say can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require… […]
Jama Software debuts medtech software
Jama Software (Portland, Ore.) announced this week that it has introduced new software for medical device development. The company described Jama Connect as a solution designed to help engineering teams better manage device requirements, risk and design control. The new software is also designed to make regulatory submissions and audit preparations a straightforward process and… […]
Could this fabric protect against a strain of coronavirus?
Noble Biomaterials announced today that third-party testing showed one of its metallized fabrics reduced the viability of a common, strong strain of coronavirus. In testing conducted by BioScience Laboratories, Noble Biomaterials’ X-Static fabric reduced the survival of human coronavirus OC43 six times faster than the unmetallized control fabric, according to the Scranton, Pa.-based company. X-Static… […]
How gas and liquid valves improve medtech performance and efficiency
While the miniature solenoid valves might be simple in their core technology, their continued evolution makes them valuable and effective components for controlling the flow, direction and pressure of gases and fluids in today’s medical devices. Paul Gant, Emerson Automation Solutions With automated functions, excellent reliability and long life, it’s no surprise that gas and liquid… […]
Astrodyne TDI and Digi-Key Electronics join forces
Power supply and EMI filter manufacturer Astrodyne TDI announced today that it has joined Digi-Key Electronics’ DK+ Marketplace, a new B2B electronics sales site open to suppliers and distributors to offer their products and services on DigiKey.com. This new venture will make Astrodyne TDI’s medical and industrial power solutions available for immediate delivery to Digi-Key’s engineering… […]
How to meet challenges with innovative machining
CNC is a technique for automating control of machine tools using software rooted in a microcomputer affixed to the tool. It is frequently used in manufacturing for machining metal and plastic parts. John Cross, Micro Data drive the accuracy and efficiency of the computerized numerical control (CNC) machines coming onto the market today. The latest… […]
Vexos to manufacture 10,000 ventilators for Canadian COVID-19 patients
Electronics manufacturer Vexos said this week that it has signed an agreement with the government of Canada to manufacture 10,000 mechanical ventilators for COVID-19 patients in that country. The LaGrange, Ohio-based company said it will build the ventilators, known as Mechanical Ventilator Milano (MVM), under an exclusive license agreement with Elemaster Group for the Americas. Vexos said… […]
Merck eyes tiny patches as a vaccine delivery method
Merck has exercised its option to use Vaxxas‘ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate, the companies announced today. The companies did not disclose what the vaccine candidate is supposed to treat. But Merck this month announced two COVID-19 vaccine development efforts: a collaboration with IAVI and plans… […]
Qioptiq to build new plant in Germany
Qioptiq announced today that it has begun construction on a new factory in Germany. A subsidiary of Excelitas Technologies, Qioptiq will invest about $27 million in the project. Located in the Göttingen Science Park industrial estate, the new site has an initial acreage of approximately 193,750 sq. ft. and will house state-of-the-art ISO 5 cleanrooms… […]
Pioneer Metal Finishing launches surface tech resource
Pioneer Metal Finishing (Green Bay, Wis.) recently announced the launch of Surface Engineering Academy (SEA), an expert-level resource for surface engineering and modification advancement. SEA’s focus on surface engineering and modification stems from the company’s goal to further develop and apply optimized product surfaces. Legacy technologies such as anodizing, plating, adhesives and coatings continue to… […]
Texas-based team seeks EUA for 3D printed emergency ventilator
A team of physicians and engineers developed a hands-free resuscitator bag compression device that can be utilized as an emergency ventilator during the COVID-19 pandemic. As the pandemic goes on and a shortage of vital equipment, including ventilators, continues, a number of companies and research teams from all over have worked to create alternative options. One… […]